Obesity pipeline
Trial arms side by side.
One row is one arm. A blank cell is n/r. A comparator gap appears only when the source states that gap.
ClassNone selected
MechanismNone selected
No arms selected. Choose a drug, an arm, or a preset.
Each arm uses its closest stored timepoint inside the window.
value
Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.
No selected arm has this endpoint inside the time window.
Show as table
| Arm | Trial | Phase | Population | n | Comparator | Timepoint | Estimand | Assessor | Value |
|---|
Not shown
Every selected arm is drawn.
299 of 2118 arms with a reported figure. Choose arms to narrow the chart.
Change in body weight, %. Discontinued for adverse events, %.
Source: Cited trial source. An arm needs both figures at the same timepoint.
Y axis: Discontinued for adverse events, %
X axis: Change in body weight, %
Show as table
| Arm | Change in body weight, % | Discontinued for adverse events, % |
|---|---|---|
| Semaglutide 7.2 mg | -18.8 | 5.4% |
| Semaglutide Placebo | -3.9 | 1% |
Not shown
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide Semaglutide placebo: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide Semaglutide: endpoint not reported
- Semaglutide Placebo (semaglutide): endpoint not reported
- Semaglutide 1.0 mg: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Semaglutide placebo I/II: endpoint not reported
- Semaglutide Semaglutide: no arm n for percent
- Semaglutide Placebo: no arm n for percent
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Placebo, in trial: endpoint not reported
- Semaglutide 15 mg: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Semaglutide placebo OW: endpoint not reported
- Semaglutide Semaglutide: endpoint not reported
- Semaglutide Semaglutide placebo: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Placebo, in trial: endpoint not reported
- Semaglutide Insuline glargine U100 (reduced) + semaglutide: endpoint not reported
- Semaglutide Insuline glargine U100 (titrated): endpoint not reported
- Semaglutide Semaglutide: endpoint not reported
- Semaglutide Placebo (semaglutide): endpoint not reported
- Semaglutide 7.2 mg: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Placebo: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide 1.7 mg: endpoint not reported
- Semaglutide 1.7 mg: endpoint not reported
- Semaglutide Semaglutide: endpoint not reported
- Semaglutide Placebo (semaglutide): endpoint not reported
- Semaglutide Semaglutide: endpoint not reported
- Semaglutide Placebo: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Placebo, in trial: endpoint not reported
- Semaglutide Placebo: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Semaglutide: endpoint not reported
- Semaglutide Placebo (semaglutide): endpoint not reported
- Semaglutide Semaglutide: endpoint not reported
- Semaglutide Placebo: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Placebo: endpoint not reported
- Semaglutide Semaglutide, on treatment: endpoint not reported
- Semaglutide Placebo, on treatment: endpoint not reported
- Tirzepatide Placebo: no arm n for percent
- Tirzepatide 5 mg: no arm n for percent
- Tirzepatide 10 mg: no arm n for percent
- Tirzepatide 15 mg: no arm n for percent
- Tirzepatide 15 mg: endpoint not reported
- Tirzepatide Placebo: endpoint not reported
- Tirzepatide 10 mg: endpoint not reported
- Tirzepatide Tirzepatide (lead-in): endpoint not reported
- Tirzepatide Tirzepatide MTD: endpoint not reported
- Tirzepatide Placebo: endpoint not reported
- Tirzepatide Tirzepatide: endpoint not reported
- Tirzepatide Placebo: endpoint not reported
- Tirzepatide Tirzepatide: endpoint not reported
- Tirzepatide Placebo: endpoint not reported
- Tirzepatide Tirzepatide MTD_GPI1: endpoint not reported
- Tirzepatide Placebo_GPI1: endpoint not reported
- Tirzepatide Tirzepatide MTD_GPI2: endpoint not reported
- Tirzepatide Placebo_GPI2: endpoint not reported
- Tirzepatide 15 mg: endpoint not reported
- Tirzepatide Placebo: endpoint not reported
- Tirzepatide 10 mg: endpoint not reported
- Tirzepatide 15 mg: endpoint not reported
- Tirzepatide Placebo: endpoint not reported
- Tirzepatide 10 mg: endpoint not reported
- Orforglipron Placebo: endpoint not reported
- Orforglipron 6 mg: endpoint not reported
- Orforglipron 12 mg: endpoint not reported
- Orforglipron Placebo QD: endpoint not reported
- Orforglipron 6 mg: endpoint not reported
- Orforglipron 12 mg: endpoint not reported
- Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg: no arm n for percent
- Cagrilintide/semaglutide Placebo s.c.: no arm n for percent
- Retatrutide 4 mg: no arm n for percent
- Retatrutide 9 mg: no arm n for percent
- Retatrutide 12 mg: no arm n for percent
- Retatrutide Placebo: no arm n for percent
- Survodutide 3.6 mg: no arm n for percent
- Survodutide 6.0 mg: no arm n for percent
- Survodutide Placebo: no arm n for percent
- Survodutide 0.6 mg: endpoint not reported
- Survodutide Placebo group: endpoint not reported
- Survodutide 2.4 mg: endpoint not reported
- Survodutide 3.6 mg: endpoint not reported
- Survodutide 4.8 mg: endpoint not reported
- VK2735 2.5 mg: no arm n for percent
- VK2735 15 mg: no arm n for percent
- VK2735 Placebo 13 weeks: no arm n for percent
- Eloralintide Placebo: no arm n for percent
- Eloralintide 1 mg: no arm n for percent
- Eloralintide 3 mg: no arm n for percent
- Eloralintide 6 mg: no arm n for percent
- Eloralintide 9 mg: no arm n for percent
- Berobenatide Placebo: endpoint not reported
- Dulaglutide Dulaglutide Arm: endpoint not reported
- Dulaglutide Placebo Arm: endpoint not reported
- Exenatide Group A: endpoint not reported
- Exenatide Group B: endpoint not reported
- Exenatide Exenatide: endpoint not reported
- Exenatide Placebo: endpoint not reported
- Exenatide Exenatide once weekly (EQW ): no arm n for percent
- Exenatide Dapagliflozin (DAPA): no arm n for percent
- Exenatide EQW plus DAPA: no arm n for percent
- Exenatide Dapagliflozin plus Glucophage (MET ER): no arm n for percent
- Exenatide Phentermine /Topiramate (PHEN/ TPM) ER: no arm n for percent
- Exenatide Exenatide once weekly extended-release: no arm n for percent
- Exenatide Matching placebo: no arm n for percent
- Exenatide Group A: endpoint not reported
- Exenatide Group B: endpoint not reported
- Liraglutide 3.0mg: no arm n for percent
- Liraglutide 3.0mg: no arm n for percent
- Liraglutide Liraglutide Placebo, no Pre-diabetes: no arm n for percent
- Liraglutide Liraglutide Placebo, Pre-diabetes: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide 1.8 mg: no arm n for percent
- Liraglutide Placebo: no arm n for percent
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide Placebo: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide Placebo: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide Placebo: endpoint not reported
- Liraglutide Semaglutide: endpoint not reported
- Liraglutide Liraglutide: endpoint not reported
- Liraglutide Placebo (liraglutide): endpoint not reported
- Liraglutide Liraglutide: endpoint not reported
- Liraglutide Placebo: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide Placebo, in trial: endpoint not reported
- Liraglutide Liraglutide: endpoint not reported
- Liraglutide Placebo: endpoint not reported
- Liraglutide Metformin XR plus liraglutide: no arm n for percent
- Liraglutide Metformin XR plus placebo: no arm n for percent
- Liraglutide Liraglutide Pen Injector (Saxenda): no arm n for percent
- Liraglutide Placebo liraglutide pen injector: no arm n for percent
- Liraglutide Liraglutide: endpoint not reported
- Liraglutide Placebo: endpoint not reported
- Liraglutide 0.05 mg: endpoint not reported
- Liraglutide 0.1 mg: endpoint not reported
- Liraglutide 0.2 mg: endpoint not reported
- Liraglutide 0.3 mg: endpoint not reported
- Liraglutide 0.4 mg: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide Placebo + Metformin: endpoint not reported
- Liraglutide Liraglutide + Metformin: endpoint not reported
- Liraglutide 100 mcg: endpoint not reported
- Liraglutide 200 mcg: endpoint not reported
- Liraglutide 300 mcg: endpoint not reported
- Liraglutide 2.4 mg: endpoint not reported
- Liraglutide 4.5 mg: endpoint not reported
- Liraglutide 1.2 mg: endpoint not reported
- Liraglutide 0.6 mg: endpoint not reported
- Liraglutide 0.3 mg: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide Orlistat: endpoint not reported
- Lixisenatide Lixisenatide: endpoint not reported
- Lixisenatide Sitagliptin: endpoint not reported
- Mazdutide 3/6 Milligrams (mg) Mazdutide: endpoint not reported
- Mazdutide 10 mg: no arm n for percent
- Mazdutide 16 mg: no arm n for percent
- Mazdutide Placebo: no arm n for percent
- Mazdutide 6 mg: no arm n for percent
- Oral Semaglutide Oral semaglutide: endpoint not reported
- Oral Semaglutide Oral semaglutide placebo: endpoint not reported
- Oral Semaglutide 25 mg: endpoint not reported
- Oral Semaglutide Oral semaglutide placebo: endpoint not reported
- Oral Semaglutide 50 mg: endpoint not reported
- Oral Semaglutide oral semaglutide placebo once daily: endpoint not reported
- TERN-601 250 mg: endpoint not reported
- TERN-601 500 mg: endpoint not reported
- TERN-601 750 mg: endpoint not reported
- TERN-601 Matching Placebo: endpoint not reported
- CT-868 CT-868 Placebo: endpoint not reported
- CT-868 1.8 mg: endpoint not reported
- CT-868 4.1 mg: endpoint not reported
- CT-868 6.6 mg: endpoint not reported
- HM15211 HM15211: endpoint not reported
- HM15211 Placebo: endpoint not reported
- Pramlintide Placebo-P + Placebo-M: endpoint not reported
- Pramlintide 360 mcg: endpoint not reported
- Pramlintide 5.0 mg: endpoint not reported
- Pramlintide 2.5 mg: endpoint not reported
- Pramlintide 5.0 mg: endpoint not reported
- Pramlintide 1.25 mg: endpoint not reported
- Pramlintide 2.5 mg: endpoint not reported
- Pramlintide 5.0 mg: endpoint not reported
- Pramlintide 1: endpoint not reported
- Pramlintide 2: endpoint not reported
- Pramlintide 3: endpoint not reported
- Pramlintide Placebo: endpoint not reported
- Pramlintide Pramlintide + Metreleptin: endpoint not reported
- Pramlintide Pramlintide Acetate and Placebo: endpoint not reported
- Pramlintide Lead-In Period: endpoint not reported
- Bimagrumab 30 mg: endpoint not reported
- Bimagrumab 30 mg: endpoint not reported
- Bimagrumab 30 mg: endpoint not reported
- Bimagrumab 1.0 mg: endpoint not reported
- Bimagrumab 2.4 mg: endpoint not reported
- Bimagrumab 1.0 mg: endpoint not reported
- Bimagrumab 2.4 mg: endpoint not reported
- Naltrexone And Bupropion NB16: endpoint not reported
- Naltrexone And Bupropion NB32: endpoint not reported
- Naltrexone And Bupropion Placebo: endpoint not reported
- Naltrexone And Bupropion NB32: endpoint not reported
- Naltrexone And Bupropion Placebo: endpoint not reported
- Naltrexone And Bupropion NB32: endpoint not reported
- Naltrexone And Bupropion Placebo: endpoint not reported
- Naltrexone And Bupropion NB32: endpoint not reported
- Naltrexone And Bupropion Placebo: endpoint not reported
- Naltrexone And Bupropion BWL + NB medication: endpoint not reported
- Naltrexone And Bupropion BWL + Placebo: endpoint not reported
- Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication: endpoint not reported
- Naltrexone And Bupropion BWL + Placebo: endpoint not reported
- Naltrexone And Bupropion NB medication: endpoint not reported
- Naltrexone And Bupropion Placebo: endpoint not reported
- Naltrexone And Bupropion Naltrexone+Bupropion Medication: endpoint not reported
- Naltrexone And Bupropion Placebo: endpoint not reported
- Naltrexone And Bupropion Naltrexone/Bupropion: endpoint not reported
- Naltrexone And Bupropion Placebo: endpoint not reported
- Orlistat Intensive Lifestyle Mod. Intervention: endpoint not reported
- Orlistat Standard Lifestyle Intervention: endpoint not reported
- Orlistat Placebo: endpoint not reported
- Orlistat Orlistat: endpoint not reported
- Phentermine And Topiramate VI-0521 Low: endpoint not reported
- Phentermine And Topiramate VI-0521 Top: endpoint not reported
- Phentermine And Topiramate Placebo: endpoint not reported
- Phentermine And Topiramate VI-0521 Top: endpoint not reported
- Phentermine And Topiramate VI-0521 Mid: endpoint not reported
- Phentermine And Topiramate TPM 46: endpoint not reported
- Phentermine And Topiramate TPM 92: endpoint not reported
- Phentermine And Topiramate PHEN 7.5: endpoint not reported
- Phentermine And Topiramate PHEN 15: endpoint not reported
- Phentermine And Topiramate Placebo: endpoint not reported
- Phentermine And Topiramate LSMT 12: endpoint not reported
- Phentermine And Topiramate LSMT 24: endpoint not reported
- Phentermine And Topiramate Phentermine & Topiramate: endpoint not reported
- Phentermine And Topiramate Placebo Drugs: endpoint not reported
- Phentermine And Topiramate Semaglutide: endpoint not reported
- Phentermine And Topiramate Other anti-obesity medication: endpoint not reported
- Setmelanotide Setmelanotide: endpoint not reported
- Setmelanotide Placebo: endpoint not reported
- Setmelanotide Setmelanotide: endpoint not reported
- Setmelanotide Setmelanotide (Double-Blind): endpoint not reported
- Setmelanotide Placebo (Double-Blind): endpoint not reported
- Setmelanotide Setmelanotide (Open-label): endpoint not reported
- Setmelanotide Pivotal Cohort: no arm n for percent
- Setmelanotide 2 mg: endpoint not reported
- Setmelanotide 2.5 mg: endpoint not reported
- Setmelanotide 3 mg: endpoint not reported
- Setmelanotide 20 mg: endpoint not reported
- Setmelanotide 25 mg: endpoint not reported
- Setmelanotide 3 mg: endpoint not reported
- Setmelanotide 30 mg: endpoint not reported
- Setmelanotide 20 mg: endpoint not reported
- Setmelanotide 25 mg: endpoint not reported
- Setmelanotide 30 mg: endpoint not reported
- Setmelanotide Setmelanotide: no arm n for percent
- Setmelanotide Setmelanotide: no arm n for percent
- Setmelanotide Setmelanotide: PPL Group: endpoint not reported
- Setmelanotide Setmelanotide: BBS Group: endpoint not reported
- Setmelanotide 16p11.2 Cohort: endpoint not reported
- Setmelanotide AS Cohort: endpoint not reported
- Setmelanotide BBS Cohort: endpoint not reported
- Setmelanotide MC4R Cohort: endpoint not reported
- Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohort: endpoint not reported
- Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohort: endpoint not reported
- Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohort: endpoint not reported
- Setmelanotide SH2B1 Cohort: endpoint not reported
- Setmelanotide SMS Cohort: endpoint not reported
- Setmelanotide SRC1 Cohort: endpoint not reported
- Setmelanotide Stage 1: Setmelanotide (Open-Label): no arm n for percent
- Setmelanotide Stage 2: Setmelanotide (Double-Blind): endpoint not reported
- Setmelanotide Stage 2: Placebo (Double-Blind): endpoint not reported
- Setmelanotide Placebo: endpoint not reported
- Setmelanotide Setmelanotide: endpoint not reported
- Setmelanotide Placebo: endpoint not reported
- Setmelanotide 0.5 mg: endpoint not reported
- Setmelanotide 1.5 mg: endpoint not reported
- Setmelanotide 2.5 mg: endpoint not reported
- Setmelanotide Placebo: endpoint not reported
- Sibutramine Sibutramine: endpoint not reported
- Sibutramine Placebo: endpoint not reported
- Tesofensine placebo arm: endpoint not reported
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.